ArticleFrontiers in genetics2025
Genome-wide analysis of long non-coding RNAs and mRNAs in lung adenocarcinoma with pulmonary thromboembolism.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary thromboembolism (PTE) is a serious complication in patients with lung adenocarcinoma (LUAD), yet its molecular mechanisms remain poorly understood. This study aimed to investigate the expression profiles of long non-coding RNAs (lncRNAs) and mRNAs in LUAD patients complicated by PTE. Methods: Peripheral blood samples were collected from LUAD patients with PTE and from three control groups (LUAD-only, PTE-only, and healthy controls). RNA sequencing was performed to identify differentially expressed lncRNAs and mRNAs among groups. Results: RNA sequencing revealed significant dysregulation of transcripts. Compared with LUAD-only patients, 725 lncRNAs and 2,052 mRNAs were differentially expressed in the LUAD + PTE group. Compared with PTE-only patients, 932 lncRNAs and 2,206 mRNAs were differentially expressed, while comparison with healthy controls identified 1,190 lncRNAs and 3,001 mRNAs. Key dysregulated transcripts included MERGE.31027.6, ENST00000318988, MERGE.30976.2, and ENST00000397519. Enrichment analyses highlighted immune response-related pathways, cytokine signaling, and the NF-κB signaling pathway. Conclusion: These findings suggest that aberrant lncRNA and mRNA expression may contribute to the pathogenesis of LUAD complicated by PTE and may serve as potential biomarkers and therapeutic targets for prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.